New drug trial aims to protect kidneys from damage

NCT ID NCT07157787

Recruiting now Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing an investigational drug called ALXN1920 in adults with primary membranous nephropathy, a serious kidney disease. The main goal is to see if ALXN1920, compared to a placebo, can reduce the amount of protein leaking into the urine, which is a key sign of kidney damage. Participants will continue their standard background medications during the trial.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
NOT_YET_RECRUITING

Loma Linda, California, 92354, United States
Research Site
RECRUITING

San Diego, California, 92123, United States
Research Site
RECRUITING

Minneapolis, Minnesota, 55435, United States
Research Site
RECRUITING

Rochester, Minnesota, 55905, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

Buenos Aires, 1425, Argentina
Research Site
RECRUITING

CABA, C1425AGC, Argentina
Research Site
RECRUITING

Ciudad de Buenos Aires, 1280, Argentina
Research Site
RECRUITING

Rosario, 2000, Argentina
Research Site
WITHDRAWN

Santa Fe, S3000EOZ, Argentina
Research Site
WITHDRAWN

Santa Fe, S3000, Argentina
Research Site
RECRUITING

Gosford, 2250, Australia
Research Site
RECRUITING

Parkville, 3050, Australia
Research Site
RECRUITING

Southport, 4222, Australia
Research Site
RECRUITING

Recife, 50670-901, Brazil
Research Site
RECRUITING

Salvador, 40301-155, Brazil
Research Site
RECRUITING

São Paulo, 04038-002, Brazil
Research Site
RECRUITING

São Paulo, 05403-000, Brazil
Research Site
RECRUITING

Baotou, 014010, China
Research Site
RECRUITING

Beijing, 100034, China
Research Site
RECRUITING

Guangzhou, 510080, China
Research Site
RECRUITING

Shenzhen, 518036, China
Research Site
WITHDRAWN

Créteil, 94010, France
Research Site
RECRUITING

Nice, 06000, France
Research Site
RECRUITING

Toulouse, 31059, France
Research Site
RECRUITING

Milan, 20122, Italy
Research Site
RECRUITING

Ranica, 24020, Italy
Research Site
RECRUITING

Torrette, 60126, Italy
Research Site
RECRUITING

Barcelona, 08025, Spain
Research Site
RECRUITING

Madrid, 28007, Spain
Research Site
RECRUITING

Seville, 41013, Spain
Research Site
RECRUITING

Toledo, 45007, Spain
Research Site
RECRUITING

Kaohsiung City, 81362, Taiwan
Research Site
RECRUITING

Taichung, 40705, Taiwan
Research Site
RECRUITING

Taoyuan District, 333, Taiwan
Research Site
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Research Site
RECRUITING

Leicester, LE5 4PW, United Kingdom
Research Site
RECRUITING

London, SE5 9RJ, United Kingdom
Research Site
RECRUITING

Salford, M6 8HD, United Kingdom

Conditions

Explore the condition pages connected to this study.

PRIMARY MEMBRANOUS NEPHROPATHY